Company intelligence / Profile preview
Infant Bacterial Therapeutics
Stockholm, Swedenibtherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Infant Bacterial Therapeutics’ lead candidate, IBP‑9414—a freeze-dried preparation of Lactobacillus reuteri—has completed Phase II and is currently in a pivotal Phase III trial (“The Connection Study”) targeting prevention of necrotizing enterocolitis and improvement of feeding tolerance in premature infants. The company has also received orphan drug designations from both FDA and EMA. Additional pipeline assets are at preclinical or early clinical stages targeting rare neonatal diseases with high unmet need such as gastroschisis, ROP, and VRE infections. No commercial products yet.
- Therapeutic areas
- GastroenterologyOphthalmologyRare DiseasesInfectious Diseases
- Modalities
- Live biotherapeutic product therapyMicrobial therapyBiologicProbiotic (specifically live bacteria as active substance)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Infant Bacterial Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Infant Bacterial Therapeutics.